EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

A vitamin D‐based strategy overcomes chemoresistance in prostate cancer

Kateryna Len-Tayon iD, Claire Beraud, Clara Fauveau, Anna Y Belorusova, Yassmine Chebaro, Antonio Mouriño, Thierry Massfelder, Anne Chauchereau, Daniel Metzger, Natacha Rochel, Gilles Laverny iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16492 ↗

At a glance

Journal article in British Journal of Pharmacology, 2024. Written by Kateryna Len-Tayon and 10 co-authors. Institution: Institute of Genetics and Molecular and Cellular Biology (IGBMC), Illkirch-Graffenstaden, France. Major MEDLINE topics: Drug Resistance, Neoplasm, Vitamin D, Docetaxel, Prostatic Neoplasms, Castration-Resistant. Cited 9 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY 4.0). Funded by: Agence Nationale de la Recherche, Canceropole Est, Ligue Contre le Cancer Est.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and purpose Castration‐resistant prostate cancer (CRPC) is a common male malignancy that requires new therapeutic strategies due to acquired resistance to its first‐line treatment, docetaxel. The benefits of vitamin D on prostate cancer (PCa) progression have been previously reported. This study aimed to investigate the effects of vitamin D on chemoresistance in CRPC. Experimental approach Structure function relationships of potent vitamin D analogues were determined. The combination of the most potent analogue and docetaxel was explored in chemoresistant primary PCa spheroids and in a xenograft mouse model derived from a patient with a chemoresistant CRPC. Key results Here, we show that Xe4MeCF3 is more potent than the natural ligand to induce vitamin D receptor (VDR) transcriptional activities and that it has a larger therapeutic window. Moreover, we demonstrate that VDR agonists restore docetaxel sensitivity in PCa spheroids. Importantly, Xe4MeCF3 reduces tumour growth in a chemoresistant CRPC patient‐derived xenograft. In addition, this treatment targets signalling pathways associated with cancer progression in the remaining cells. Conclusion and implications Taken together, these results unravel the potency of VDR agonists to overcome chemoresistance in CRPC and open new avenues for the clinical management of PCa.

Subjects

MeSH terms (MEDLINE)

Drug Resistance, NeoplasmVitamin DDocetaxelProstatic Neoplasms, Castration-ResistantReceptors, CalcitriolMaleHumansAnimalsMiceAntineoplastic AgentsCell Line, TumorStructure-Activity RelationshipXenograft Model Antitumor Assays

Author keywords

castration resistant prostate cancerdocetaxel resistancepatient‐derived xenograftsspheroidsvitamin D analogues

Substances

Vitamin DDocetaxelReceptors, CalcitriolAntineoplastic Agents

Authors and institutions

  • Institute of Genetics and Molecular and Cellular Biology (IGBMC), Illkirch-Graffenstaden, France.
  • CNRS UMR 7104, Illkirch-Graffenstaden, France.
  • Inserm U1258, Illkirch-Graffenstaden, France.
  • University of Strasbourg, Illkirch-Graffenstaden, France.
  • Urosphere, Toulouse, France.
  • Transgene SA, Illkirch-Graffenstaden, France.

ORCID profiles: Kateryna Len-Tayon, Gilles Laverny

Funding

  • Agence Nationale de la Recherche
  • Canceropole Est
  • Ligue Contre le Cancer Est
  • SATT Conectus
  • Association pour La Recherche sur les Tumeurs Prostatiques (ARTP)
  • Institut National du Cancer
  • Ministry of Higher Education and Research
  • Fondation ARC pour la Recherche sur le Cancer

Cite

APA

Len-Tayon, K., Beraud, C., Fauveau, C., Belorusova, A. Y., Chebaro, Y., Mouriño, A., Massfelder, T., Chauchereau, A., Metzger, D., Rochel, N., & Laverny, G. (2024). A vitamin D‐based strategy overcomes chemoresistance in prostate cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16492

Vancouver

Len-Tayon K, Beraud C, Fauveau C, Belorusova AY, Chebaro Y, Mouriño A, et al. A vitamin D‐based strategy overcomes chemoresistance in prostate cancer. British Journal of Pharmacology. 2024. doi:10.1111/bph.16492

BibTeX
@article{LenTayon2024,
  author = {Len-Tayon, Kateryna and Beraud, Claire and Fauveau, Clara and Belorusova, Anna Y and Chebaro, Yassmine and Mouriño, Antonio and Massfelder, Thierry and Chauchereau, Anne and Metzger, Daniel and Rochel, Natacha and Laverny, Gilles},
  title = {A vitamin D‐based strategy overcomes chemoresistance in prostate cancer},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16492}
}
Start for free →